BREAST CANCER AND HORMONES

    Recommened Journal Articles:

    Bilimoria, M. M., et al. “Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics.” Annals of Surgical Oncology, 1999, 6: 200-7.

    Bluming, A.Z., et al. “Hormone replacement therapy in women with previously treated primary breast cancer.” Proceedings of the Annual Metting of the American Society of Clinical Oncology, 1994, Abstract A137.

    Bonnier, P., et al. “Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy.” Obstetrics and Gynecology, 1995, 85: 11.

    Chang, K. J., et al. “Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo.” Fertility and Sterility, April 1995, 63 (4): 785-91.

    Cowan, L. D., et al. “Breast cancer incidence in women with ahistory of progesterone deficiency.” American Journal of Epidemiology, August 1981, 114 (2): 209-17.

    Dew, J., et al. “A cohort study of hormonal replacement therapy given to women previously treated for breast cancer.” Climacteric, 1998, 1: 137-42.

    DiSaia, P. J., et al. “Hormone replacement in breast cancer.” Lancet, 1993, 342: 1232.

    DiSaia, P. J., et al. “Hormone replacement therapy in breast cancer survivors: A cohort study.” American Journal of Obstetrics and Gynecology, 1996, 174: 1494-98.

    Eden, J. A., et al. “A case-controlled study of combined continuous estrogen-progestin replacement therapy amongst women with a personal history of breast cancer.” Menopause, 1995, 2: 67-72.

    Ewertz┬áM. “Influences of noncontraceptive exogenous sex hormones on breast cancer risk in Denmark.” Cited by Gambrell, presentation paper.

    Foidart, J., et al. “Estradiol and progesterone regulate the proliferation of human breast epithelial cells.” Fertility and Sterility, May 1998, 69 (5): 963-68.

    Formby, B., and Wiley, T. S. “Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53.” Annals of Clinical Laboratory Sci, November-December 1998, 28 (6): 360-9.

    Formby, B., and Wiley, T. S. “Bcl-2, surviving and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis.” Mol Cell Biochem, December 1999, 202 (1-2): 53-61.

    Gajdos, Csaba, et al. “Breast cancer diagnosed during hormone replacement therapy.” Obstetrics and Gynecology, April 2000, 95 (4): 513-18.

    Gambrell, R. Don, et al. “Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users.” Obstetrics-Gynecology, October 1983, 62 (4): 435-43.

    Gambrell, R. Don, Jr. “Hormone replacement therapy and breast cancer.” Maturitas, August 1987, 9 (2): 123-33.

    Gambrell, R. Don, Jr. “Hormone replacement therapy and breast cancer risk.” Archives of Family Medicine, June 1996, 5: 341-50.

    Helzlsouer, Kathy, et al. “Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.” Cancer Research, January, 1992, 52: 1-4.

    Holli, K., et al. “Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.” Journal of Clinical Oncology, 1998, 16: 3115-20.

    Holmes, Michelle D., et al. “Association of dietary intake of fat and fatty acids with risk of breast cancer.” Journal of the American Medical Association, March 10, 1999, 281 (10): 914-20.

    Hortobagyi, G. I., et al. “Sequential cyclic combined hormonal therapy for metastatic breast cancer.” Cancer, 1989, 64: 1002-6.

    Johnson, Kate. “ERT halves testosterone levels, may warrant Tx.” Ob-Gyn News, May 15, 2000, 35 (10): 18.

    Lavigne, J. A., et al. “An association between the allele coding for a low activity variant of catechol-O-methyl transferase and the risk for breast cancer.” Cancer Research, December 15, 1997, 57 (24): 5493-7.